Compare New York Times Co (NYT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs BIO-TECHNE Corp — how do they compare? New York Times Co trades at $66.3 (market cap $10.74B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: New York Times Co and BIO-TECHNE Corp are close in size by market cap, and New York Times Co pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and BIO-TECHNE Corp for 63 Days on average.
| NYT | TECH | |
|---|---|---|
Market Cap | $10.74B | $11.36B |
Volume | 2,096,352 | 5,390,331 |
Sector | Media | Health |
52-Week High | $85.86 | $72.61 |
52-Week Low | $54.66 | $43.31 |
Typical Hold Time | 81 Days | 63 Days |
Enterprise Value | $10.14B | $11.39B |
Dividend Yield | 1.38% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $64.90, up 1.3% with strong fundamentals including 12.17% net margin and consistent earnings beats. Technical indicators show bearish momentum with support at $62-64 and resistance at $65-67. Recent news highlights dividend declaration and ongoing AI copyright litigation.
Outlook remains positive with 35% analyst buy ratings and $84 consensus target, though legal risks and technical bearish signals warrant caution. Revenue growth trajectory and strong profitability support long-term value despite near-term headwinds.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
